Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26


Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells.

Sterner RM, Cox MJ, Sakemura R, Kenderian SS.

J Vis Exp. 2019 Jul 22;(149). doi: 10.3791/59629.


[Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy].

Shimizu R, Sakemura R, Iwata S, Hayakawa H, Miyao K, Kajiguchi T.

Rinsho Ketsueki. 2019;60(5):365-371. doi: 10.11406/rinketsu.60.365. Japanese.


Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

Khadka RH, Sakemura R, Kenderian SS, Johnson AJ.

Immunotherapy. 2019 Jul;11(10):851-857. doi: 10.2217/imt-2019-0074. Epub 2019 Jun 4. No abstract available.


GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS.

Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21.


Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease Tissues.

Koyama D, Murata M, Hanajiri R, Akashi T, Okuno S, Kamoshita S, Julamanee J, Takagi E, Miyao K, Sakemura R, Goto T, Terakura S, Nishida T, Kiyoi H.

Biol Blood Marrow Transplant. 2019 Mar;25(3):417-423. doi: 10.1016/j.bbmt.2018.10.012. Epub 2018 Oct 22.


Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study.

Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, Takahashi T, Sakemura R, Kojima H, Kohno A, Oba MS, Morita S, Sakamoto J, Emi N.

Int J Clin Oncol. 2018 Oct;23(5):980-988. doi: 10.1007/s10147-018-1300-9. Epub 2018 May 29.


Introduction of Genetically Modified CD3ζ Improves Proliferation and Persistence of Antigen-Specific CTLs.

Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2018 Jun;6(6):733-744. doi: 10.1158/2326-6066.CIR-17-0538. Epub 2018 Apr 13.


Successful Treatment of a Case of Late-onset Colitis after Umbilical Cord Transplantation with Metronidazole: A Case Report and Literature Review.

Sakemura R, Hayakawa H, Iida H, Ito M, Kajiguchi T.

Intern Med. 2017 Dec 1;56(23):3219-3223. doi: 10.2169/internalmedicine.8948-17. Epub 2017 Oct 11. Review.


High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype.

Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, Takagi E, Hirano D, Miyao K, Sakemura R, Goto T, Hayakawa F, Seto A, Ozawa Y, Miyamura K, Terakura S, Nishida T, Kiyoi H.

PLoS One. 2017 Sep 25;12(9):e0185213. doi: 10.1371/journal.pone.0185213. eCollection 2017.


Interdigitating dendritic cell sarcoma successfully treated with ABVD therapy in which serum CEA levels correlated with disease activity.

Sakemura R, Hiraga J, Kitagawa S, Ito M, Kajiguchi T, Mizuno S.

Rinsho Ketsueki. 2017;58(4):292-297. doi: 10.11406/rinketsu.58.292. Japanese.


Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Kurahashi S, Ozawa Y, Goto T, Imahashi N, Nishida T, Miyao K, Sakemura R, Kato T, Sawa M, Kohno A, Sao H, Iida H, Kiyoi H, Naoe T, Miyamura K, Murata M.

Bone Marrow Transplant. 2017 Apr;52(4):612-614. doi: 10.1038/bmt.2016.323. Epub 2017 Jan 9. No abstract available.


The Efficacy of an Oral Elemental Diet in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Morishita T, Tsushita N, Imai K, Sakai T, Miyao K, Sakemura R, Kato T, Niimi K, Ono Y, Sawa M.

Intern Med. 2016;55(24):3561-3569. Epub 2016 Dec 15.


A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.

Miyao K, Sawa M, Kurata M, Suzuki R, Sakemura R, Sakai T, Kato T, Sahashi S, Tsushita N, Ozawa Y, Tsuzuki M, Kohno A, Adachi T, Watanabe K, Ohbayashi K, Inagaki Y, Atsuta Y, Emi N.

Int J Hematol. 2017 Jan;105(1):79-86. doi: 10.1007/s12185-016-2095-y. Epub 2016 Sep 30.


Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.

Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H.

J Immunother. 2016 Oct;39(8):306-15. doi: 10.1097/CJI.0000000000000136.


A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.

Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H.

Cancer Immunol Res. 2016 Aug;4(8):658-68. doi: 10.1158/2326-6066.CIR-16-0043. Epub 2016 Jun 21.


Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Watanabe K, Imahashi N, Terakura S, Ohashi H, Akatsuka Y, Kurahashi S, Miyamura K, Kiyoi H, Nishida T, Naoe T.

Bone Marrow Transplant. 2015 Sep;50(9):1187-94. doi: 10.1038/bmt.2015.119. Epub 2015 Jun 1.


Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.

Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watamoto K, Kohno A, Kasai M, Kato C, Iida H, Naoe T, Miyamura K, Murata M; Nagoya Blood and Marrow Transplantation Group.

Ann Hematol. 2015 Jul;94(7):1139-48. doi: 10.1007/s00277-015-2312-4. Epub 2015 Feb 15.


Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.

Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M.

J Immunother. 2015 Feb-Mar;38(2):62-70. doi: 10.1097/CJI.0000000000000069.


Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.

Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M.

J Immunol. 2015 Feb 1;194(3):911-20. doi: 10.4049/jimmunol.1402346. Epub 2014 Dec 17.


Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma.

Miyao K, Sakemura R, Imai K, Sakai T, Tsushita N, Kato T, Niimi K, Ono Y, Sawa M.

Int J Hematol. 2014 Aug;100(2):152-8. doi: 10.1007/s12185-014-1608-9. Epub 2014 Jun 20.


Supplemental Content

Loading ...
Support Center